Label: TADALAFIL tablet, coated

Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.

• The yellow Cialis pill is often marketed with medical claims about ED treatment.
• Online ordering of yellow Cialis should be done cautiously to avoid scams.
• Yellow Cialis is used by men seeking a reliable solution for ED.
• The pill's color helps distinguish it from other ED medications like Viagra.
• Dosage adjustments for yellow Cialis depend on individual health factors.
• The yellow Cialis pill can be taken on an empty stomach for quicker results.
• The safety profile of yellow Cialis has been established through clinical trials.
• Cialis, including the yellow dosage form, is prescribed worldwide.
• Regular monitoring by a healthcare provider enhances safe use of yellow Cialis.
• The yellow Cialis pill is an effective, long-lasting option for ED.
• Potential interactions with other medications should be managed under medical advice.
• The yellow Cialis pill is a widely trusted medication for ED management.

Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period.

• The yellow Cialis pill is a popular choice due to its reliability and effectiveness.
• It is essential to get proper medical evaluation before starting yellow Cialis.
• The brand's distinctive yellow color supports easy identification and safety.
• Yellow Cialis should be stored away from moisture and heat.
• The pill’s design includes specific markings for safety during manufacturing.
• Duration of effectiveness makes yellow Cialis suitable for planned or spontaneous use.
• Avoid taking yellow Cialis with certain real or herbal supplements without consultation.
• The yellow Cialis pill helps improve self-confidence in men with ED.
• Always use yellow Cialis under the guidance of a healthcare professional.
• The pill’s pharmacokinetics allows for up to 36 hours of efficacy.
• Be aware of possible side effects such as nasal congestion and muscle aches.
• Proper use of yellow Cialis can significantly improve quality of life.

A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitors has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds.

Cialis Drug Class

In many cases, medical follow -up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, cialis lily or to other factors [see Warnings and Precautions ( 5.4) and Patient Counseling Information ( 17)] .Urogenital—Priapism [see Warnings and Precautions ( 5.6)] . The following serious adverse reactions are discussed elsewhere in the labeling: Hypotension [see Warnings and Precautions ( 5.1)] Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)] Hearing loss [see Warnings and Precautions ( 5.4)] Priapism [see Warnings and Precautions ( 5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.

How much to take

In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. Cardiovascular and cerebrovascular—Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications ( 4.1)] .

Patient resources

It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole—Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous—Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic—Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]. Otologic—Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions ( 5.4) and Patient Counseling Information ( 17)] . Patients 10mg cialis price who have conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk.

Product	Dosage	Quantity + Bonus	Price
Cialis Professional	20mg	90 + 2 Pills	241.49€ 229.99€	Buy
Cialis Generic	20mg	360 + 10 Pills	427.34€ 406.99€	Buy
Cialis Generic	40mg	270 + 10 Pills	382.19€ 363.99€	Buy
Cialis Professional	20mg	10 Pills	48.29€ 45.99€	Buy
Cialis Original	20mg	8 Pills	61.70€ 58.76€	Buy
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€	Buy
Cialis Generic	60mg	20 Pills	65.61€ 62.49€	Buy
Cialis Super Active	20mg	20 + 4 Pills	92.35€ 87.95€	Buy
Cialis Generic	2.5mg	180 + 10 Pills	154.86€ 147.49€	Buy
Cialis Professional	20mg	120 + 4 Pills	291.68€ 277.79€	Buy
Cialis Black	80mg	20 Pills	71.83€ 68.41€	Buy

Tadalafil has vasodilatory properties that may result in transient decreases in blood pressure. Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil.

Potential for Interaction

Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] . Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions ( 5.1)]Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]Hearing loss [see Warnings and Precautions ( 5.4)]Priapism [see Warnings and Precautions ( 5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide.

Ingredient	Amount per Dose	Purpose	Notes
Tadalafil	20 mg	Active ingredient, vasodilator	Main component for ED
Microcrystalline Cellulose	-	Filler	Binds ingredients
Magnesium Stearate	-	Excipient	Improves pill stability
Titanium Dioxide	-	Coloring agent	Provides yellow color

In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse discount cialis online no prescription event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular—Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications ( 4.1)] .

• Physical features of yellow Cialis include smooth coating and visible markings.
• Patients should avoid alcohol and grapefruit products while taking yellow Cialis.
• The yellow color of Cialis pills signifies it's a PDE5 inhibitor.
• The yellow Cialis pill is designed for quick absorption in the bloodstream.
• Before use, check the packaging for authenticity of the yellow Cialis.
• Side effects like dizziness may occur after taking yellow Cialis.
• The yellow Cialis pill is known for its consistency in quality.
• Cialis's active ingredient, tadalafil, is responsible for its effects.
• Always follow dosing guidelines to prevent potential health risks.
• The yellow Cialis pill enhances sexual performance by improving blood flow.
• Education about yellow Cialis helps patients use it effectively.
• Medical consultation is essential when considering yellow Cialis treatment.

Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole—Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous—Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic—Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)].Otologic—Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. In many cases, medical follow -up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, cialis lily or to other factors [see Warnings and Precautions ( 5.4) and Patient Counseling Information ( 17)] .Urogenital—Priapism [see Warnings and Precautions ( 5.6)] . The following serious adverse reactions are discussed elsewhere in the labeling: Hypotension [see Warnings and Precautions ( 5.1)] Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)] Hearing loss [see Warnings and Precautions ( 5.4)] Priapism [see Warnings and Precautions ( 5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Tadalafil was administered to 398 patients with PAH during clinical trials worldwide.

1.1 Pulmonary Arterial Hypertension

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] . Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions ( 5.1)]Visual Loss [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]Hearing loss [see Warnings and Precautions ( 5.4)]Priapism [see Warnings and Precautions ( 5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide.

Understanding PAH and BPH

In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse discount cialis online no prescription event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors.

Tadalafil may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular—Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications ( 4.1)] . Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole—Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous—Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic—Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)].Otologic—Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.

5. A different version of tadalafil also exists

Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥50 in the general population. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, typical of erectile dysfunction treatment, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.5.4 Hearing ImpairmentCases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

Your questions answered

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions ( 6.2)] .5.5 Combination with Other PDE5 InhibitorsTadalafil is also marketed for erectile dysfunction. The safety and efficacy of taking tadalafil tablets together with another PDE5 inhibitors has not been studied. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors.5.6 Prolonged ErectionThere have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. Patients 10mg cialis price who have conditions that might predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia), or in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease) are at an increased risk. Tadalafil has vasodilatory properties that may result in transient decreases in blood pressure.

Driving or using machines

Patients with preexisting hypotension,with autonomic dysfunction, with left ventricular outflow obstruction, may be particularly sensitive to the actions of vasodilators. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Should signs of pulmonary edema occur when tadalafil tablets are administered, the possibility of associated PVOD should be considered. When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including tadalafil. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by ≥9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. Cardiovascular and cerebrovascular—Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications ( 4.1)] . It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole—Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous—Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic—Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions ( 5.3) and Patient Counseling Information ( 17)]. Otologic—Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions ( 5.4) and Patient Counseling Information ( 17)] .